Partner Scott Fredericksen was interviewed on the CBS Evening News about the indictment of President Trump’s longtime confidant and former campaign advisor Roger Stone on seven counts of lying, obstruction and witness tampering in connection with special counsel Robert Mueller’s investigation into Russian interference in the 2016 presidential election.
Fredericksen said the charges against Stone should worry the president. ”The tantalizing question in this indictment is whether it was the president who directed a senior campaign official to be in contact with Mr. Stone about whether there was going to be more of the Russian-hacked emails from the Democratic Party, ” he said.
Fredericksen said the charges against Stone should worry the president. ”The tantalizing question in this indictment is whether it was the president who directed a senior campaign official to be in contact with Mr. Stone about whether there was going to be more of the Russian-hacked emails from the Democratic Party, ” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”